STOCK TITAN
  1. Home
  2. Sec-filings
  3. LCTX
  4. [EFFECT] Lineage Cell Therapeutics, Inc. SEC Filing

[EFFECT] Lineage Cell Therapeutics, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: March 23, 2026 4:30 P.M.
Form: S-3
CIK: 0000876343
Company Name: Lineage Cell Therapeutics, Inc.
File Number: 333-294202

Source: View Original Filing on SEC EDGAR

Lineage Cell The

NYSE:LCTX

View LCTX Stock Overview →

LCTX Rankings

#3781 Ranked by Market Cap
N/A Ranked by Dividends

LCTX Latest News

Mar 24, 2026
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease
Mar 5, 2026
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Feb 26, 2026
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
Jan 6, 2026
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
Jan 5, 2026
Lineage Cell Therapeutics Issues Letter to Stockholders

LCTX Latest SEC Filings

Mar 12, 2026
[Form 4] Lineage Cell Therapeutics, Inc. Insider Trading Activity
Mar 11, 2026
[8-K] Lineage Cell Therapeutics, Inc. Reports Material Event
Mar 11, 2026
[S-3] Lineage Cell Therapeutics, Inc. Shelf Registration Statement
Mar 11, 2026
[424B5] Lineage Cell Therapeutics, Inc. Prospectus Supplement (Debt Securities)
Mar 6, 2026
[Form 4] Lineage Cell Therapeutics, Inc. Insider Trading Activity

LCTX Stock Data

361.18M
236.64M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
CARLSBAD